Back to Network
7
Shared Docs
7
Same-Page
7 / 7
Mentions
Document Mentions (7 shared documents)
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
55607 EFTA02454076 High Strike Current Yield Yield Advantage over Stock Stock Upside to Price Tgt Stock Up 25%: Pfd Return Stock Down 25%: Pfd Return Notional Outstanding AGN (AGNprA) 5.5% 3/1/18 252.95 893.45 288.00 352.80 6.2% 6.2% 1 - Buy $ 294.00 16.2% 22.7% -15.5% $5.06bn TEVA
2 mentions1 same-page
Page ?Same page
l to drive shareholder return. N=xt catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm :=17;s US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval=of AGN generics deal. We continue to like TEVA's positioning in generic=pharma where
High Strike Current Yield Yield Advantage over Stock BAML Ranking (Stock) BAML Price Tgt (Stock) Stock Upside to Price Tgt S=ock Up 25%: Pfd Return S=ock Down 25%: Pfd Return N=tional Outstanding AGN =AGNprA) 5.5% 3/1/18 252.95 893.45 288.00 4 EFTA_R1_01556245 EFTA02454471 352.80 6.2%
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
d Yield Advantage over Stock BAML Ranking (Stock) BAML Price Tgt (Stock) Stock Upside to Price Tgt Stock Up 25%: Pfd Return Stock Down 25%: Pfd Return Notional Outstanding AGN (AGNprA) 5.5% 3/1/18 252.95 893.45 288.00 8 EFTA_R1_01557878 EFTA02455325 352.80 6.2% 6.2% 1 - Buy $ 294.00
Sponsored
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
11 EFTA_R1_01556638 EFTA02454709 Ranking (Stock) BAML Price Tgt (Stock) Stock Upside to Price Tgt Stock Up 25%: Pfd Return Stock Down 25%: Pfd Return Notional Outstanding AGN (AGNprA) 5.5% 3/1/18 252.95 893.45 288.00 352.80 6.2% 6.2% 1 - Buy $ 294.00 16.2% 22.7% -15.5% S5.06bn TEVA
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
d Yield Advantage over Stock BAML Ranking (Stock) BAML Price Tgt (Stock) Stock Upside to Price Tgt Stock Up 25%: Pfd Return Stock Down 25%: Pfd Return Notional Outstanding AGN (AGNprA) 5.5% 3/1/18 11 EFTA_R1_01555899 EFTA02454271 252.95 893.45 288.00 352.80 6.2% 6.2% 1 - Buy $ 294.00
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
ispricing FTR. Name High Strike Current Yield Yield Advantage over Stock Stock Upside to Price Tgt Stock Up 25%: Pfd Return Stock Down 25%: Pfd Return Notional Outstanding AGN (AGNprA) 5.5% 3/1/18 252.95 893.45 288.00 352.80 6.2% 6.2% 11 EFTA_R1_01556379 EFTA02454570 1 - Buy $ 294.00
Sponsored
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
d Yield Advantage over Stock BAML Ranking (Stock) BAML Price Tgt (Stock) Stock Upside to Price Tgt Stock Up 25%: Pfd Return Stock Down 25%: Pfd Return Notional Outstanding AGN (AGNprA) 5.5% 3/1/18 12 EFTA_R1_001 07691 EFTA01785510 252.95 893.45 288.00 352.80 6.2% 6.2% 1 - Buy $ 294.00
Sponsored
Mutual Connections (31)
Entities connected to both Teva Pharma and Pfd Return
Jeffrey Epstein
PERSON11 w/ Teva·7 w/ Pfd
Marc Rich
PERSON11 w/ Teva·7 w/ Pfd
Paul Volcker
PERSON11 w/ Teva·7 w/ Pfd
Richard Kahn
PERSON11 w/ Teva·7 w/ Pfd
HM
Hans Mikkelsen
PERSON11 w/ Teva·7 w/ Pfd
Bloomberg L.P.
ORGANIZATION11 w/ Teva·7 w/ Pfd
Frontier Communications
ORGANIZATION11 w/ Teva·7 w/ Pfd
Chart One
ORGANIZATION11 w/ Teva·7 w/ Pfd
US Treasury ETF
ORGANIZATION11 w/ Teva·7 w/ Pfd
S&P500 ETF
ORGANIZATION11 w/ Teva·7 w/ Pfd
Investment Grade Supply
ORGANIZATION11 w/ Teva·7 w/ Pfd
Investment Grade ETF
ORGANIZATION11 w/ Teva·7 w/ Pfd
Frontier Comm
ORGANIZATION10 w/ Teva·7 w/ Pfd
Allergan
LOCATION9 w/ Teva·7 w/ Pfd
Spec Pharma
ORGANIZATION10 w/ Teva·6 w/ Pfd
AM
Amanda
PERSON8 w/ Teva·4 w/ Pfd
AE
Amanda Ens
PERSON7 w/ Teva·4 w/ Pfd
Outlook
ORGANIZATION6 w/ Teva·4 w/ Pfd
Non-Farm Payrolls
ORGANIZATION6 w/ Teva·3 w/ Pfd
Bloomberg: Junk Debt Keeps Climbing Despite Plunging Oil Prices
ORGANIZATION6 w/ Teva·3 w/ Pfd